23 Sep

Neogen’s Performance Compared to Its Peers

WRITTEN BY Gabriel Kane

Neogen and its peers

An analysis of Neogen’s income statement in 1Q16 follows:

  • The gross profit margins of Neogen (NEOG), IDEXX Laboratories (IDXX), Bio-Rad Laboratories (BIO), Thermo Fisher Scientific (TMO), VWR (VWR), and Bio-Techne (TECH) are 50.48%, 56.31%, 55.25%, 45.47%, 27.61%, and 67.22%, respectively.

Neogen’s Performance Compared to Its Peers

  • The EPS (earnings per share) of Neogen, IDEXX Laboratories, Bio-Rad Laboratories, Thermo Fisher Scientific, VWR, and Bio-Techne are $0.25, $0.60, $0.97, $1.28, $0.14, and $0.69, respectively.

An analysis of Neogen’s balance sheet in 1Q16 follows:

  • The current ratio of Neogen, IDEXX Laboratories, Bio-Rad Laboratories, Thermo Fisher Scientific, VWR, and Bio-Techne are 8.74, 1.07, 4.31, 1.02, 1.51, and 6.24, respectively.

An analysis of Neogen’s valuation follows:

  • The PE (price-to-earnings) ratios of Neogen, IDEXX Laboratories, Bio-Rad Laboratories, Thermo Fisher Scientific, VWR, and Bio-Techne are 54.84x, 40.66x, 41.95x, 25.83x, 17.01x, and 32.82x, respectively.
  • The PBV (price-to-book value) ratios of Neogen, Bio-Rad Laboratories, Thermo Fisher Scientific, VWR, and Bio-Techne are 5.22x, 1.72x, 2.43x, 2.65x, and 4.16x, respectively.

According to the above findings, Neogen outperformed its peers based on the current ratio, PE ratio, and PBV ratio. However, based on the gross profit margin and EPS, the peers are way ahead of Neogen.

ETFs that invest in Neogen 

The PowerShares S&P SmallCap Health Care ETF (PSCH) invests 2.20% of its holdings in Neogen. PSCH tracks a cap-weighted index of small-cap healthcare companies taken from the S&P SmallCap 600 Index.

The SPDR S&P Health Care Equipment ETF (XHE) invests 1.16% of its holdings in Neogen. XHE tracks an equal-weighted index of US healthcare equipment and supply companies.

The PowerShares DWA SmallCap Momentum ETF (DWAS) invests 0.67% of its holdings in Neogen. DWAS tracks an index of 200 small-cap securities with the best relative strength indicators. These indicators are determined by Dorsey Wright’s proprietary methodology.

Neogen compared to its ETFs

An analysis of Neogen’s price movement follows:

  • The YTD (year-to-date) price movements of Neogen, PSCH, XHE, and DWAS are -0.46%, 22.41%, -45.11%, and 3.57%, respectively.

An analysis of Neogen’s valuation follows:

  • The PE ratios of Neogen, PSCH, XHE, and DWAS are 54.84x, 52.49x, 98.31x, and 79.70x, respectively.
  • The PBV ratios of Neogen, PSCH, XHE, and DWAS are 5.22x, 3.47x, 4.36x, and 4.04x, respectively.

According to the above findings, the ETFs outperformed Neogen based on the price movement and PE ratio. Based on the PBV ratio, Neogen is way ahead of its ETFs.

Latest articles

23 Jul

Will Fortinet Beat Q2 Earnings Estimates?

WRITTEN BY Aditya Raghunath

Leading cybersecurity company Fortinet (FTNT) is scheduled to announce its second-quarter earnings results on August 1. What should we expect?

Harley-Davidson’s Q2 earnings were slightly better than estimates.

Netflix (NFLX) has long relied on international markets to drive its streaming video business growth.

23 Jul

Could Ford’s Q2 Earnings Push Its Stock Even Higher?

WRITTEN BY Mohit Oberoi, CFA

Ford's second-quarter earnings results are scheduled for release on July 24. So far, Ford stock has outperformed its legacy peers.

23 Jul

Why RBC Isn't Optimistic about BlackBerry Stock

WRITTEN BY Aditya Raghunath

Shares of BlackBerry (BB) have been volatile over the last 12 months. BlackBerry stock fell 40.5% from $12.0 in September 2018 to $6.57 in December.

According to a Wall Street Journal report, Apple (AAPL) could be interested in buying Intel’s modem chip business.